NIKKEI 225
38,398.73 +296.29 (+0.78%) HANG SENG
17,903.06 -33.06 (-0.18%) CRUDE OIL
80.15 -0.18 (-0.22%) GOLD FUTURES
2,336.80 +7.80 (+0.33%) DOW
38,778.10 +188.94 (+0.49%) Bitcoin GBP
51,771.00 -559.44 (-1.07%)
Roche Holding AG (ROG.SW)
| Previous close | 247.60 |
| Open | 247.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 243.50 - 247.10 |
| 52-week range | 212.90 - 279.35 |
| Volume | |
| Avg. volume | 1,346,905 |
| Market cap | 198.473B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 17.16 |
| EPS (TTM) | 14.31 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 9.60 (3.88%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 271.95 |
ZacksRoche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCLData were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentatio
Business WireGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., June 15, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of
